Activation of the Innate Immune System Provides Broad-spectrum Protection Against Influenza A Viruses with Pandemic Potential in Mice

Overview

Journal Virology

Specialty Microbiology

Date 2010 Jul 30

PMID 20667572

Citations 26

Authors

Yuk-Fai Lau

Lay-Hoon Tang

Eng-Eong Ooi

Kanta Subbarao

Affiliations

Soon will be listed here.

Abstract

The efficacy of a stabilized chemical analog of double-stranded ribonucleic acid (RNA), PIKA, as prophylaxis against infection with 5 different influenza A virus subtypes, including the 2009 swine-origin pandemic H1N1 virus, was evaluated in mice. Intranasal treatment with PIKA resulted in a significant reduction of viral replication in the respiratory tract. The inhibitory effect was mediated by rapid infiltration of immune cells into the lungs, and production of inflammatory cytokines. While TLR3 is important for the optimal production of these inflammatory cytokines, inhibition of viral replication was still observed in TLR3(-/-) mice. In addition, a significant synergistic effect in inhibiting H5N1 virus replication was observed when PIKA was coadministered with oseltamivir. The broad-spectrum protection provided by PIKA makes it an attractive option for prophylaxis from infection with influenza A viruses.

Citing Articles

Safety, tolerability, and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine in healthy adults: an open-label randomized phase I clinical trial.

Lim R, Qiu X, Leong R, Gutierrez J, Halima A, Mostafa M Clin Exp Vaccine Res. 2024; 13(4):315-328.

PMID: 39525677 PMC: 11543792. DOI: 10.7774/cevr.2024.13.4.315.

Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.

Lim R, Qiu X, Alberto E, Capeding M, Carlos J, Leong R Clin Exp Vaccine Res. 2024; 13(4):329-337.

PMID: 39525672 PMC: 11543791. DOI: 10.7774/cevr.2024.13.4.329.

Meeting the Challenge of Controlling Viral Immunopathology.

Berber E, Mulik S, Rouse B Int J Mol Sci. 2024; 25(7).

PMID: 38612744 PMC: 11011832. DOI: 10.3390/ijms25073935.

Toll-like Receptor Mediation in SARS-CoV-2: A Therapeutic Approach.

Manan A, Pirzada R, Haseeb M, Choi S Int J Mol Sci. 2022; 23(18).

PMID: 36142620 PMC: 9502216. DOI: 10.3390/ijms231810716.

Toll-like receptor-agonist-based therapies for respiratory viral diseases: thinking outside the cell.

Girkin J, Maltby S, Bartlett N Eur Respir Rev. 2022; 31(164).

PMID: 35508333 PMC: 9488969. DOI: 10.1183/16000617.0274-2021.

References

Wong J, Saravolac E, Sabuda D, Levy H, KENDE M . Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother. 1995; 39(11):2574-6. PMC: 162988. DOI: 10.1128/AAC.39.11.2574. View

Morrey J, Day C, Julander J, Blatt L, Smee D, Sidwell R . Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother. 2004; 15(2):101-9. DOI: 10.1177/095632020401500202. View

Trinchieri G, Sher A . Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007; 7(3):179-90. DOI: 10.1038/nri2038. View

Stokes J, Sorkness R, Kaplan M, Castleman W, Tomai M, Miller R . Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur Respir J. 1998; 11(2):324-9. DOI: 10.1183/09031936.98.11020324. View

Hurt A, Selleck P, Komadina N, Shaw R, Brown L, Barr I . Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2006; 73(3):228-31. DOI: 10.1016/j.antiviral.2006.10.004. View

De Miranda J, Yaddanapudi K, Hornig M, Lipkin W . Astrocytes recognize intracellular polyinosinic-polycytidylic acid via MDA-5. FASEB J. 2008; 23(4):1064-71. PMC: 2660646. DOI: 10.1096/fj.08-121434. View

Saravolac E, Sabuda D, Crist C, Blasetti K, Schnell G, Yang H . Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine. 2001; 19(17-19):2227-32. DOI: 10.1016/s0264-410x(00)00450-3. View

Lipatov A, Govorkova E, Webby R, Ozaki H, Peiris M, Guan Y . Influenza: emergence and control. J Virol. 2004; 78(17):8951-9. PMC: 506949. DOI: 10.1128/JVI.78.17.8951-8959.2004. View

Kumar H, Koyama S, Ishii K, Kawai T, Akira S . Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol. 2008; 180(2):683-7. DOI: 10.4049/jimmunol.180.2.683. View

10.

McKimm-Breschkin J, Selleck P, Usman T, Johnson M . Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis. 2008; 13(9):1354-7. PMC: 2857286. DOI: 10.3201/eid1309.070164. View

11.

Tuvim M, Evans S, Clement C, Dickey B, Gilbert B . Augmented lung inflammation protects against influenza A pneumonia. PLoS One. 2009; 4(1):e4176. PMC: 2613561. DOI: 10.1371/journal.pone.0004176. View

12.

Hayden F . Antiviral resistance in influenza viruses--implications for management and pandemic response. N Engl J Med. 2006; 354(8):785-8. DOI: 10.1056/NEJMp068030. View

13.

Chen M, Griffith B, Lucia H, Hsiung G . Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother. 1988; 32(5):678-83. PMC: 172251. DOI: 10.1128/AAC.32.5.678. View

14.

Morens D, Taubenberger J, Fauci A . Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008; 198(7):962-70. PMC: 2599911. DOI: 10.1086/591708. View

15.

Peiris M, Yuen K, Leung C, Chan K, Ip P, Lai R . Human infection with influenza H9N2. Lancet. 1999; 354(9182):916-7. DOI: 10.1016/s0140-6736(99)03311-5. View

16.

Nakano H, Yanagita M, Gunn M . CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med. 2001; 194(8):1171-8. PMC: 2193516. DOI: 10.1084/jem.194.8.1171. View

17.

Samuel C . Antiviral actions of interferons. Clin Microbiol Rev. 2001; 14(4):778-809, table of contents. PMC: 89003. DOI: 10.1128/CMR.14.4.778-809.2001. View

18.

Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K . Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008; 205(7):1601-10. PMC: 2442638. DOI: 10.1084/jem.20080091. View

19.

Izurieta H, Thompson W, Kramarz P, Shay D, Davis R, DeStefano F . Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000; 342(4):232-9. DOI: 10.1056/NEJM200001273420402. View

20.

Wong J, Yang H, Nagata L, KENDE M, Levy H, Schnell G . Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine. 1999; 17(13-14):1788-95. DOI: 10.1016/s0264-410x(98)00439-3. View